Hudson Bay Capital Management LP Buys 7,502 Shares of Intuitive Surgical, Inc. $ISRG

Hudson Bay Capital Management LP grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,132 shares of the medical equipment provider’s stock after buying an additional 7,502 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Intuitive Surgical were worth $29,129,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ISRG. Kilter Group LLC bought a new stake in Intuitive Surgical in the 2nd quarter valued at $27,000. Greykasell Wealth Strategies Inc. acquired a new position in Intuitive Surgical in the 3rd quarter worth $27,000. Caitlin John LLC bought a new position in Intuitive Surgical during the 3rd quarter worth about $30,000. Riggs Asset Managment Co. Inc. increased its holdings in Intuitive Surgical by 84.2% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 32 shares in the last quarter. Finally, KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Intuitive Surgical in the 3rd quarter valued at about $33,000. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on ISRG shares. Barclays set a $712.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a research report on Monday, January 26th. Wall Street Zen lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Raymond James Financial boosted their target price on Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price target for the company in a research report on Wednesday, March 11th. Finally, Royal Bank Of Canada raised their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $614.95.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $477.73 on Thursday. The company has a market cap of $169.66 billion, a price-to-earnings ratio of 60.55, a P/E/G ratio of 3.72 and a beta of 1.66. The firm has a 50-day moving average of $507.10 and a 200-day moving average of $512.85. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The business had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the business earned $2.21 earnings per share. Intuitive Surgical’s quarterly revenue was up 18.8% on a year-over-year basis. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Company fundamentals and market positioning — Intuitive reported a strong January quarter (beats on revenue and EPS, ~19% revenue growth year‑over‑year) and is pursuing lower‑cost da Vinci systems to target fast‑growing ambulatory surgery centers, which could expand procedure volume outside hospitals over time. No external link
• Neutral Sentiment: Sector and competitive news with limited direct impact — other medtech product launches and approvals in the broader ecosystem (e.g., Merit Medical’s new esophageal stent) are being reported but do not directly displace Intuitive’s robotic surgery franchise. MMSI Launches Resilience TTS Stent for Esophageal Fistulas, Strictures
• Negative Sentiment: FDA regulatory flag — Intuitive was flagged by the FDA over a medical device issue, which raises near‑term regulatory and operational risk concerns; such notices can prompt customer caution, warranty/repair costs, or increased oversight that pressure sentiment. Intuitive Surgical flagged by FDA over medical device issue
• Negative Sentiment: Analyst outlook softened — UBS cut its price target from $570 to $550 and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure; the new target still implies some upside versus current levels but reflects more cautious sentiment. Intuitive Surgical (NASDAQ:ISRG) Price Target Lowered to $550.00 at UBS Group

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 421 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total value of $208,378.16. Following the completion of the sale, the executive vice president owned 409 shares of the company’s stock, valued at approximately $202,438.64. This represents a 50.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 2,362 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $498.68, for a total transaction of $1,177,882.16. Following the completion of the transaction, the senior vice president directly owned 3,554 shares of the company’s stock, valued at $1,772,308.72. This represents a 39.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 32,943 shares of company stock valued at $17,279,568. 0.70% of the stock is owned by insiders.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.